- Home
- TVRD vs ABEO Comparison
TVRD vs ABEO Comparison
Compare TVRD & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVRD
- ABEO
- Stock Information
- Founded
- TVRD 2017
- ABEO 1974
- Country
- TVRD United States
- ABEO United States
- Employees
- TVRD N/A
- ABEO N/A
- Industry
- TVRD Biotechnology: Pharmaceutical Preparations
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- TVRD Health Care
- ABEO Health Care
- Exchange
- TVRD Nasdaq
- ABEO Nasdaq
- Market Cap
- TVRD 246.5M
- ABEO 256.9M
- IPO Year
- TVRD N/A
- ABEO 1980
- Fundamental
- Price
- TVRD $28.34
- ABEO $6.24
- Analyst Decision
- TVRD Strong Buy
- ABEO Strong Buy
- Analyst Count
- TVRD 2
- ABEO 5
- Target Price
- TVRD $52.00
- ABEO $17.80
- AVG Volume (30 Days)
- TVRD 48.4K
- ABEO 1.7M
- Earning Date
- TVRD 05-13-2025
- ABEO 05-15-2025
- Dividend Yield
- TVRD N/A
- ABEO N/A
- EPS Growth
- TVRD N/A
- ABEO N/A
- EPS
- TVRD N/A
- ABEO N/A
- Revenue
- TVRD N/A
- ABEO N/A
- Revenue This Year
- TVRD N/A
- ABEO N/A
- Revenue Next Year
- TVRD N/A
- ABEO $383.07
- P/E Ratio
- TVRD N/A
- ABEO N/A
- Revenue Growth
- TVRD N/A
- ABEO N/A
- 52 Week Low
- TVRD $8.13
- ABEO $3.93
- 52 Week High
- TVRD $34.31
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- TVRD N/A
- ABEO 56.57
- Support Level
- TVRD N/A
- ABEO $5.93
- Resistance Level
- TVRD N/A
- ABEO $7.17
- Average True Range (ATR)
- TVRD 0.00
- ABEO 0.44
- MACD
- TVRD 0.00
- ABEO -0.01
- Stochastic Oscillator
- TVRD 0.00
- ABEO 50.00
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.